Cullinan Oncology and Taiho Pharmaceutical announced that Taiho was acquiring Cullinan Pearl and will co-develop and co-commercialize a non-small cell lung cancer (NSCLC) drug.
https://www.pharmalive.com/wp-content/uploads/2022/05/BioSpaceDeal5-12-2022.jpg350625BioSpacehttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngBioSpace2022-05-12 12:17:032022-05-12 12:22:56Cullinan Oncology and Taiho reunite to co-develop NSCLC drug